Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) closed at $111.81 in the last session, down -1.83% from day before closing price of $113.89. In other words, the price has decreased by -$1.83 from its previous closing price. On the day, 0.75 million shares were traded. RYTM stock price reached its highest trading level at $116.0 during the session, while it also had its lowest trading level at $110.45.
Ratios:
We take a closer look at RYTM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.64 and its Current Ratio is at 2.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Buy rating and assigned the stock a target price of $97.
On July 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $88.
BofA Securities Upgraded its Neutral to Buy on April 07, 2025, while the target price for the stock was maintained at $63.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 28 ’25 when Shulman Joseph sold 2,815 shares for $115.01 per share. The transaction valued at 323,750 led to the insider holds 8,509 shares of the business.
JOSEPH SHULMAN bought 9,748 shares of RYTM for $1,110,200 on Oct 30 ’25. On Oct 28 ’25, another insider, JOSEPH SHULMAN, who serves as the Officer of the company, bought 2,815 shares for $111.55 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 7426430464 and an Enterprise Value of 7394874368. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.52. Its current Enterprise Value per Revenue stands at 47.316 whereas that against EBITDA is -42.038.
Stock Price History:
The Beta on a monthly basis for RYTM is 2.13, which has changed by 1.2813711 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $115.12, while it has fallen to a 52-week low of $45.90. The 50-Day Moving Average of the stock is 8.95%, while the 200-Day Moving Average is calculated to be 49.72%.
Shares Statistics:
According to the various share statistics, RYTM traded on average about 588.87K shares per day over the past 3-months and 516040 shares per day over the past 10 days. A total of 63.91M shares are outstanding, with a floating share count of 61.39M. Insiders hold about 7.57% of the company’s shares, while institutions hold 94.99% stake in the company. Shares short for RYTM as of 1760486400 were 5574246 with a Short Ratio of 9.47, compared to 1757894400 on 5220961. Therefore, it implies a Short% of Shares Outstanding of 5574246 and a Short% of Float of 10.76.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.45 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.17 and -$3.41 for the fiscal current year, implying an average EPS of -$2.95. EPS for the following year is -$1.88, with 10.0 analysts recommending between -$0.63 and -$3.42.
Revenue Estimates
According to 13 analysts,. The current quarter’s revenue is expected to be $50.71M. It ranges from a high estimate of $53M to a low estimate of $48M. As of. The current estimate, Rhythm Pharmaceuticals Inc’s year-ago sales were $33.25MFor the next quarter, 13 analysts are estimating revenue of $54.58M. There is a high estimate of $59M for the next quarter, whereas the lowest estimate is $50.5M.
A total of 14 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $193.2M, while the lowest revenue estimate was $179.91M, resulting in an average revenue estimate of $186.38M. In the same quarter a year ago, actual revenue was $130.13MBased on 14 analysts’ estimates, the company’s revenue will be $303.81M in the next fiscal year. The high estimate is $367.1M and the low estimate is $265M.
